Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection -an Open Label Randomized Controlled Trial
Launched by AKIL AL ISLAM · May 30, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to compare two different treatments for a common stomach infection called Helicobacter pylori (H. pylori), which can cause symptoms like stomach pain and discomfort (known as dyspepsia). The study will evaluate how well a standard treatment called triple therapy works compared to a more intensive treatment called quadruple therapy. To confirm if the treatment is effective, participants will take a test four weeks after finishing their medication to see if the H. pylori infection has been eliminated.
To join this trial, participants must be at least 18 years old and have a confirmed H. pylori infection through specific tests. They should not have received treatment for H. pylori in the past, nor take certain medications before the trial. Participants will need to provide their consent to join and agree to follow-up appointments after treatment. Throughout the trial, researchers will also monitor any side effects that may arise from the treatments. This study is currently not yet recruiting participants, but it aims to help improve how we treat H. pylori infections in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All dyspeptic patients aged ≥18 years. 2. Patients with positive CLO test and Stool antigen test both. 3. Patients who will provide informed written consent and agree to follow-up at 4 weeks post-treatment.
- • -
- Exclusion Criteria:
- • 1. Patients who have received prior H. pylori eradication therapy.
- • 2. Ingestion of antibiotics or proton pump inhibitor within the prior 4 weeks.
- • 3. Patients with known allergies or intolerance to any of the study medications. 4. Patients with alarm symptoms (e.g., unexplained weight loss, persistent vomiting, gastrointestinal bleeding, dysphagia).
- • 5. Patients with a history of gastric surgery. 6. Pregnant or lactating women.
- • -
About Akil Al Islam
Akil Al Islam is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on ethical practices and rigorous scientific methodologies, the organization collaborates with healthcare professionals, researchers, and regulatory bodies to facilitate the development of new therapies across various therapeutic areas. By prioritizing patient safety and data integrity, Akil Al Islam aims to contribute significantly to the global healthcare landscape and bring groundbreaking treatments to market efficiently and responsibly.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dhaka, , Bangladesh
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported